Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $47.6 million.

  • Ironwood Pharmaceuticals' Cash from Operations rose 38136.57% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.7 million, marking a year-over-year decrease of 4549.12%. This contributed to the annual value of $103.5 million for FY2024, which is 4354.76% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Cash from Operations stood at $47.6 million for Q3 2025, which was up 38136.57% from -$15.1 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Cash from Operations registered a high of $80.2 million during Q1 2023, and its lowest value of -$15.1 million during Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' median Cash from Operations value was $47.6 million (recorded in 2025), while the average stood at $46.1 million.
  • Over the last 5 years, Ironwood Pharmaceuticals' Cash from Operations had its largest YoY gain of 38136.57% in 2025, and its largest YoY loss of 14502.61% in 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Cash from Operations (Quarter) stood at $64.6 million in 2021, then increased by 22.63% to $79.2 million in 2022, then crashed by 54.74% to $35.8 million in 2023, then tumbled by 57.54% to $15.2 million in 2024, then surged by 212.76% to $47.6 million in 2025.
  • Its Cash from Operations stands at $47.6 million for Q3 2025, versus -$15.1 million for Q2 2025 and $20.0 million for Q1 2025.